Model-specific selection of molecular targets for heart failure gene therapy

Michael G. Katz, Anthony S. Fargnoli, Catherine E. Tomasulo, Louella A. Pritchette, Charles R. Bridges

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Heart failure (HF) is a complex multifaceted problem of abnormal ventricular function and structure. In recent years, new information has been accumulated allowing for a more detailed understanding of the cellular and molecular alterations that are the underpinnings of diverse causes of HF, including myocardial ischemia, pressure-overload, volume-overload or intrinsic cardiomyopathy. Modern pharmacological approaches to treat HF have had a significant impact on the course of the disease, although they do not reverse the underlying pathological state of the heart. Therefore gene-based therapy holds a great potential as a targeted treatment for cardiovascular diseases. Here, we survey the relative therapeutic efficacy of genetic modulation of β-adrenergic receptor signaling, Ca 2+ handling proteins and angiogenesis in the most common extrinsic models of HF.

Original languageEnglish
Pages (from-to)573-586
Number of pages14
JournalJournal of Gene Medicine
Issue number10
StatePublished - Oct 2011
Externally publishedYes


  • Angiogenesis
  • Animal models
  • Ca handling proteins
  • Gene therapy
  • Heart failure
  • β-adrenergic signaling


Dive into the research topics of 'Model-specific selection of molecular targets for heart failure gene therapy'. Together they form a unique fingerprint.

Cite this